Join to View Full Profile
110 Irving St Nw # 2a38Washington, DC 20010
Phone+1 202-877-2844
Dr. Shenoy is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Aarthi Shenoy is a Washington, DC-based oncologist with significant experience in Hematology and Medical Oncology. She completed her residency in Internal Medicine at the University of California (San Diego) Medical Center and her fellowship at the National Institutes of Health Clinical Center. Dr. Shenoy is a respected researcher with multiple publications on COVID-19 convalescent plasma therapy and the inflammatory responses after SARS-CoV-2 infection. She has been the lead investigator in various clinical trials, including trials related to SARS-CoV-2 and leukemia treatments. Dr. Shenoy's dedication to her field has been recognized with awards such as the CMS Meaningful Use Stage 1 Certification from ARIA Medical Oncology EMR, Varian Medical Systems in 2012 and 2014.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2004 - 2007
University of California (San Diego) Medical CenterResidency, Internal Medicine, 1997 - 2000
University of Iowa Roy J. and Lucille A. Carver College of MedicineClass of 1997
Certifications & Licensure
CA State Medical License 1999 - Present
DC State Medical License 2008 - 2026
MD State Medical License 2010 - 2023
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ARIA Medical Oncology EMR, Varian Medical Systems, 2012, 2014
Clinical Trials
- Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML Start of enrollment: 2009 Oct 01
- Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs Start of enrollment: 2013 Jul 01
- Convalescent Plasma to Limit SARS-CoV-2 Associated Complications Start of enrollment: 2020 Jun 03
Publications & Presentations
PubMed
- 3 citationsOutpatient COVID-19 convalescent plasma recipient antibody thresholds correlated to reduced hospitalizations within a randomized trial.Han-Sol Park, Anna Yin, Caelan Barranta, John S Lee, Christopher A Caputo
JCI Insight. 2024-03-14 - 2 citationsCOVID-19 convalescent plasma therapy decreases inflammatory cytokines: a randomized controlled trial.Feben Habtehyimer, Xianming Zhu, Andrew D Redd, Kelly A Gebo, Alison G Abraham
Microbiology Spectrum. 2024-01-11 - Creating a plasma coordination center to support COVID-19 outpatient trials across a national network of hospital blood banks.Anusha Yarava, Christi Marshall, David E Reichert, Aaron Ye, Preeti Khanal
Journal of Clinical and Translational Science. 2024-01-01
Press Mentions
MedStar Wants Recovered Coronavirus Patients to Donate PlasmaMay 15th, 2020
Charles and Mary Latham Fund Awards Three Research Grants to MedStar Health Research InstituteFebruary 9th, 2016
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
